Bristol Myers Squibb Stock Rises After Solid Earnings. But These Problems Remain.

Core Viewpoint - Total revenue increased during the quarter, but competition negatively impacted the drugmaker's legacy portfolio [1] Group 1 - The drugmaker experienced growth in total revenue for the quarter [1] - Competitive pressures have affected the performance of the company's legacy products [1]